MedTech Dive February 14, 2024
Nick Paul Taylor

Masimo’s OTC device, which costs nearly $300, will compete with consumer pulse oximeters that are widely available but lack FDA clearance.

Dive Brief:

  • Masimo received Food and Drug Administration clearance for the first over-the-counter (OTC) medical fingertip pulse oximeter, the company said Tuesday.
  • The FDA, which noted the lack of cleared OTC devices in its 2022 pulse oximeter review, granted 510(k) clearance to Mightysat after finding it substantially equivalent to a prescription Masimo product that came to market in 2019.
  • Masimo’s OTC device, which costs $299.99, will compete with consumer pulse oximeters that are available at drug stores and online but lack FDA clearance. In 2021, the FDA advised consumers that all the OTC pulse oximeters then on the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider, Technology, Wearables
Medtronic buys surgical instrument developer Fortimedix
Shippable ‘Health Cube’ Hospital In A Box Integrates With 400 Medical Devices
Med tech industry uses global reach to compete for innovation leadership at MEDICA and COMPAMED
Medtronic reports higher quarterly revenue, raises sales outlook for 2025
Decisions that could impact medical devices under Trump administration: 4 notes

Share This Article